The global plasma therapy market size was valued at USD 620 million in 2025 and is projected to grow from USD 666.50 million in 2026 to USD 1188.69 million by 2034, registering a CAGR of 7.5% during the forecast period from 2026 to 2034. North America dominated the plasma therapy market with a market share of 38.5% in 2025.
Plasma Therapy refers to medical treatments that use blood plasma or plasma-derived components to support healing, treat specific medical conditions, and promote tissue regeneration. These therapies may include platelet-rich plasma, convalescent plasma, and other plasma-based treatments used across various healthcare applications. Demand is increasing due to advancements in regenerative medicine, growing interest in minimally invasive treatments, and expanding research into plasma-based therapeutic applications.
Download a Free Sample To learn more about this report,
Increasing Development of Specialized Plasma-Derived Therapeutics
The plasma therapy market is increasingly focused on developing specialized plasma-derived medicines for the treatment of immunological, neurological, hematological, and other serious medical conditions. Manufacturers are expanding therapeutic portfolios and exploring new applications for plasma-derived proteins to address unmet patient needs.
Growing Adoption of Advanced Plasma Fractionation and Manufacturing Technologies
Automation, improved purification processes, and optimized manufacturing systems can help manufacturers enhance production efficiency and maintain high product-quality standards. This trend is supporting technological modernization across plasma processing and manufacturing operations.
In July 2025, plasma therapy manufacturers continued investing in advanced fractionation, purification, automation, and manufacturing technologies to improve production efficiency and operational performance.
Growing Prevalence of Immunological and Chronic Diseases
The increasing prevalence of immune deficiencies, autoimmune disorders, neurological conditions, and other chronic diseases is supporting demand for plasma-derived therapies. The growing patient population requiring specialized therapies therefore represents a fundamental driver for the plasma therapy market.
In April 2025, healthcare organizations continued emphasizing the growing treatment needs associated with chronic, immunological, and complex medical conditions.
High Cost of Plasma Collection and Therapeutic Production
Plasma-derived therapies require extensive collection, screening, testing, fractionation, purification, and quality-control processes. Maintaining specialized collection centers and highly regulated manufacturing facilities can result in substantial operational expenses. These high production costs can contribute to expensive treatment prices and create affordability challenges for healthcare systems and patients.
In June 2025, plasma therapy manufacturers continued managing significant collection, processing, and quality-control costs associated with producing specialized plasma-derived medicines.
Increasing Demand for Plasma-Derived Therapies in Emerging Healthcare Markets
Growing healthcare investment and improving access to specialized medical treatments are creating opportunities for plasma therapy providers in emerging markets. Expanding diagnostic capabilities and greater awareness of immunological and rare diseases can increase the identification of patients requiring plasma-derived therapies. This expansion of healthcare access represents an important growth opportunity for market participants.
In September 2025, healthcare development initiatives continued supporting improved access to specialized treatments and advanced therapies across emerging healthcare markets.
Maintaining a Reliable and Sustainable Plasma Supply
Fluctuations in donor participation, collection capacity, regulatory requirements, and supply-chain operations can affect the availability of raw plasma for therapeutic manufacturing. Maintaining a reliable and sustainable plasma supply while meeting growing global demand remains a significant challenge for the market.
In November 2025, plasma collection organizations and therapeutic manufacturers continued focusing on strengthening donor participation and collection networks to support the long-term availability of plasma-derived medicines.
Pure Platelet-rich Plasma Segment Dominated the Market with 34.2% Share in 2025
The pure platelet-rich plasma segment dominated the global Plasma Therapy Market with a 34.2% share in 2025, driven by its extensive use in regenerative medicine, orthopedic treatments, sports injury management, and aesthetic procedures. Its ability to promote tissue repair, accelerate healing, and reduce recovery time has made it one of the most widely adopted plasma therapy products across healthcare settings.
The leukocyte-rich PRP and pure platelet-rich fibrin segments are witnessing steady growth as clinicians increasingly use these therapies for wound healing, musculoskeletal disorders, and dental procedures. Their enhanced regenerative potential and growing clinical acceptance continue to support demand across both treatment categories.
The leukocyte-rich fibrin and plasma proteins segments are also expanding steadily due to their increasing applications in chronic wound management, reconstructive surgery, and advanced regenerative therapies. Ongoing research into plasma-derived biologics and improvements in preparation techniques are expected to further strengthen the adoption of these therapies.
Request Customizationto receive a tailored report.
Autologous Segment Dominated the Market with 71.8% Share in 2025
The autologous segment dominated the global Plasma Therapy Market with a 71.8% share in 2025, supported by its high safety profile, minimal risk of immune rejection, and lower chances of disease transmission. Since the plasma is derived from the patient's own blood, autologous therapy remains the preferred option for a wide range of regenerative and therapeutic applications.
The allogenic segment is witnessing steady growth as advancements in donor screening, plasma processing technologies, and quality control measures improve the safety and availability of donor-derived plasma products. Increasing demand for standardized plasma therapies and broader clinical applications continues to support the expansion of this segment.
Growing research into regenerative medicine, improvements in plasma preservation techniques, and expanding clinical trials are expected to create additional opportunities for both autologous and allogenic plasma therapies in the coming years.
Orthopedic Segment Dominated the Market with 34.6% Share in 2025
The orthopedic segment dominated the global Plasma Therapy Market with a 34.6% share in 2025, driven by the increasing use of platelet-rich plasma therapies for treating tendon injuries, ligament damage, osteoarthritis, and sports-related injuries. Growing preference for minimally invasive regenerative treatments continues to strengthen the segment's leading position.
The dermatology and chronic infectious diseases segments are witnessing steady growth as plasma-based therapies gain wider acceptance in skin rejuvenation, hair restoration, chronic wound healing, and infection management. At the same time, dental applications continue to expand with the increasing use of plasma therapy for bone regeneration, implant procedures, and periodontal treatments.
The cardiac muscle injury and nerve injury segments are also growing steadily due to ongoing research into regenerative therapies aimed at improving tissue repair and functional recovery. Continued advancements in regenerative medicine and expanding clinical evidence are expected to support broader adoption of plasma therapy across these specialized applications.
Hospitals & Clinics Segment Dominated the Market with 82.5% Share in 2025
The hospitals & clinics segment dominated the global Plasma Therapy Market with an 82.5% share in 2025, supported by the availability of advanced treatment facilities, experienced healthcare professionals, and increasing patient preference for hospital-based regenerative therapies. Rising adoption of plasma therapy across orthopedic, dermatology, and surgical departments continues to reinforce the segment's leading position.
The research institutions segment is witnessing steady growth as academic organizations, biotechnology companies, and clinical research centers continue to investigate new therapeutic applications for plasma-based treatments. Increasing investments in regenerative medicine research and expanding clinical trials are accelerating innovation within the segment.
Growing collaboration between healthcare providers, research organizations, and biotechnology companies is expected to further strengthen the development and commercialization of advanced plasma therapies, supporting long-term market expansion across both end-user segments.
Speak to an Analystto discuss market opportunities.
North America plasma therapy market accounted for 38.5% of the global market, reaching USD 240 million in 2025, and is projected to grow at a CAGR of 12.6% during the forecast period. Rising demand for regenerative medicine, increasing use of platelet-rich plasma (PRP) therapies, and growing adoption of minimally invasive treatments continue to drive regional market growth. Expanding sports medicine and orthopedic applications are also supporting market expansion.
The U.S. market was valued at USD 204 million in 2025, making it the largest contributor in North America. Growing demand for regenerative therapies, increasing sports injury treatments, and strong investments in advanced healthcare technologies continue to strengthen market growth.
Canada's market reached USD 36 million in 2025. Rising adoption of plasma-based treatments, expanding orthopedic care, and increasing awareness of regenerative medicine continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe plasma therapy market accounted for 27.4% of the global market, reaching USD 170 million in 2025, and is expected to register a CAGR of 11.8% during the forecast period. Increasing demand for advanced wound care, growing use of plasma therapy in orthopedics and cosmetic procedures, and rising healthcare investments are driving regional growth. Ongoing clinical research is further supporting market development.
Germany's market accounted for USD 49 million in 2025. Strong healthcare infrastructure, increasing adoption of regenerative medicine, and growing research in biologic therapies continue to support market growth.
The UK market was valued at USD 34 million in 2025. Rising demand for minimally invasive treatments, expanding sports medicine services, and increasing healthcare spending continue to contribute to market expansion.
Asia Pacific plasma therapy market accounted for 22.6% of the global market, valued at USD 140 million in 2025, and is projected to register a CAGR of 15.4% during the forecast period. Expanding healthcare infrastructure, growing awareness of regenerative medicine, increasing medical tourism, and rising demand for advanced treatment options continue to accelerate regional market growth.
Japan's market generated USD 25 million in 2025. Increasing use of regenerative therapies, strong research capabilities, and growing demand for advanced orthopedic treatments continue to support market growth.
China's market accounted for USD 73 million in 2025, representing the largest share within Asia Pacific. Expanding healthcare investments, increasing clinical applications of plasma therapy, and growing demand for regenerative medicine continue to drive market expansion.
Latin America plasma therapy market accounted for 6.8% of the global market, reaching USD 40 million in 2025, and is projected to grow at a CAGR of 12.9% during the forecast period. Improving healthcare infrastructure, rising adoption of advanced treatment methods, and increasing demand for orthopedic and wound care therapies continue to support regional market growth.
Brazil's market reached USD 20 million in 2025. Growing healthcare investments, increasing use of plasma therapy in sports medicine, and expanding access to regenerative treatments continue to create growth opportunities across the country.
Middle East & Africa plasma therapy market accounted for 4.7% of the global market, totaling USD 30 million in 2025, and is anticipated to grow at a CAGR of 11.5% during the forecast period. Rising healthcare investments, increasing awareness of regenerative medicine, and expanding specialty healthcare services are supporting regional market growth.
The UAE market was valued at USD 11 million in 2025. Growing investments in advanced healthcare facilities, rising demand for cosmetic and orthopedic procedures, and increasing adoption of innovative regenerative therapies continue to drive market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Breast Cancer Liquid Biopsy Market Size, Share, Growth, Analysis, 2034
Biodefense Market Size, Share, Growth, Analysis, Report, 2034
Automated Microbiology Market Size, Share, Growth, Analysis, 2034
Tuberculosis Testing Market Size, Share, Growth, Analysis, 2034
Colloids (Blood Plasma) Market Size, Share, Growth, Analysis, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com